Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma	Primary Central Nervous System Hodgkin Lymphoma	Recruiting	Phase 2	2025-07-31		NCT04961515

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Affiliated Hospital of Zhejiang University	201
First People's Hospital of Hangzhou	58
Huzhou Central Hospital	31
Jinhua Central Hospital	29
Jinhua People's Hospital	11
Second Affiliated Hospital of Wenzhou Medical University	81
Second Affiliated Hospital, Zhejiang University, School of Medicine	561
Sir Run Run Shaw Hospital	117
Wenzhou Central Hospital	10
Yinzhou Hospital Affiliated to Medical School of Ningbo University	2
Zhejiang Provincial People's Hospital	74
Zhejiang Provincial Tongde Hospital	20

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
2nd Affiliated Hospital, School of Medicine, Zhejiang University	Hangzhou	China	8